Veramyst (fluticasone furoate nasal spray) / GSK - LARVOL DELTA

Serum cathepsin K as a biomarker of osteoclast activation in relation to the dose and type of inhaled corticosteroids in asthma (ERS 2026) - "Results 104 patients received low-dose, 135 moderate-dose, and 13 high-dose ICS (budesonide, beclomethasone, ciclesonide, fluticasone furoate/propionate)...Conclusion Cathepsin K is positively associated with hip densitometric parameters in patients with asthma, indicating a complex role in bone remodeling. These data support its potential as a osteoporosis biomarker in patients treated with ICS and suggest its possible use in everyday clinical practice to guide the introduction of supplementary therapy."

Biomarker • Asthma • Immunology • Osteoporosis • Respiratory Diseases • CTSK

Late Breaking Abstract - A Phase III, Randomized, Multicentre, Active controlled study to evaluate Fluticasone Furoate, Umeclidinium and Vilanterol in Uncontrolled Asthma Management (ERS 2026) - "Aims and objectives: To assess efficacy and tolerability of a FDC of Fluticasone Furoate 200 mcg, Umeclidinium 62.5 mcg and Vilanterol 25 mcg compared with FDC of Indacaterol 150 mcg, Glycopyrronium 50 mcg and Mometasone furoate 160 mcg powder for inhalation in bronchial asthma Methods Adults patients with moderate-to-severe uncontrolled asthma were enrolled in the study. The FDC of FF/UME/VI was non-inferior to IND/GLY/MF in improving lung function (trough FEV₁) in uncontrolled asthma. Both treatments were well tolerated."

Clinical • Late-breaking abstract • P3 data • Asthma • Immunology • Respiratory Diseases

Persistent T2 inflammation must be assessed in context of recent inhaled corticosteroid exposure in patients with symptoms of asthma (ERS 2026) - P | "Cumulative fluticasone furoate dose (cFF, mg) was calculated...Conclusion Given the effect of ICS on FeNO, knowledge regarding prior ICS exposure is crucial in assessment of T2 inflammation in patients with asthma, while stable PBE relative to ICS exposure suggests that this may be a robust biomarker. In this cohort, those who remained persistently biomarker elevated, and had higher ICS exposure, were more likely to progress to biologic therapy."

Clinical • Asthma • Immunology • Inflammation • Respiratory Diseases

Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study. (PubMed, Adv Ther) - "There was no significant difference in pneumonia risks for BUD and fluticasone (FF/FP) among patients with moderate to severe asthma."

Journal • Retrospective data • Asthma • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

As-Needed Versus Regular Intranasal Corticosteroid Therapy in Pediatric Perennial Allergic Rhinitis: A Randomized Double-Dummy Trial. (PubMed, Ann Allergy Asthma Immunol) - "Regular INCS use was associated with greater early clinical and antiinflammatory benefits than as-needed use in pediatric PAR, without increased adverse events. However, between-group clinical differences were not sustained through week 8. As-needed treatment also improved outcomes from baseline and may be an alternative for symptom control in selected patients."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics

The efficacy of oral montelukast versus intranasal fluticasone furoate in reducing the severity of pediatric sleep-disordered breathing: A randomized clinical trial. (PubMed, Int J Pediatr Otorhinolaryngol) - "Both montelukast and fluticasone furoate reduced the pediatric SDB severity. While both medications significantly decreased adenoid size, only montelukast significantly decreased tonsillar size. Therefore, fluticasone furoate may be appropriate for adenoid hypertrophy, while montelukast is favored for concurrent tonsillar hypertrophy. These treatments may serve as alternatives to surgery in selected cases. Further studies are needed to evaluate their long-term efficacy."

Clinical • Journal • CNS Disorders • Obstructive Sleep Apnea • Pediatrics • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Safety Profile of Intranasal Corticosteroids in Allergic Rhinitis: A Comprehensive Review. (PubMed, Biomedicines) - "Formulations such as mometasone furoate, fluticasone propionate, fluticasone furoate, and ciclesonide exhibit pharmacokinetic characteristics associated with minimal systemic exposure because of extensive first-pass metabolism and low oral bioavailability...Pediatric evidence is generally reassuring, although historical concerns regarding growth suppression associated with earlier corticosteroid formulations continue to influence clinical practice. Currently available evidence supports the use of modern INCS as effective and generally well-tolerated therapeutic options across adult and pediatric populations."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation • Metabolic Disorders • Pediatrics

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial. (PubMed, J Allergy Clin Immunol Glob) - "Addition of the long-acting muscarinic antagonist umeclidinium (UMEC) to the inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination fluticasone furoate/vilanterol (FF/VI) improved lung function in adults with uncontrolled moderate to severe asthma in the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study; however, the impact on symptoms requires further investigation...The CAPTAIN study was a phase IIIA, randomized, controlled, 24- to 52-week study of patients with uncontrolled moderate to severe asthma despite ICS/LABA receiving once-daily single-inhaler FF/VI (100/25 or 200/25 μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, or 200/62.5/25 μg)...Similar trends were observed irrespective of type 2 status. Patients with symptomatic asthma may benefit from optimized treatment interventions, such as adding a long-acting muscarinic antagonist to ICS/LABA."

Journal • P1/2 data • P3 data • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Adjuvant Use of Intranasal Fluticasone Furoate to Improve Graft Uptake in Type 1 Tympanoplasty Cases: A Comparative Study. (PubMed, Ann Afr Med) - "Adjuvant topical intranasal FF demonstrated clinically meaningful improvement in tympanoplasty graft success rates with an excellent safety profile. Despite narrowly missing statistical significance, the substantial reduction in graft failure rates suggests fluticasone represents a promising, cost-effective intervention worthy of incorporation into standard posttympanoplasty protocols."

Journal • Inflammation • Otorhinolaryngology

Fluticasone Furoate-Oxymetazoline Hydrochloride Combination Nasal Spray for Managing Allergic Rhinitis With Nasal Congestion: Current Evidence and Clinical Implications. (PubMed, Cureus) - "Clinical evidence has shown that short-term use (≤14 days) of the FF+OXY (27.5/50 µg) FDC nasal spray provides rapid and sustained relief without a significant risk of RM. While few clinical trials have demonstrated the potential efficacy and safety of this FDC, there is a need for additional clinical trials and real-world evidence, given the widespread use of the FF+OXY (27.5/50 µg) FDC nasal spray for managing moderate to severe AR with nasal congestion in India."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation

Comparison of long-term (52 week therapy) maintenance vs. as-needed intranasal corticosteroid therapy in pediatric allergic rhinitis: assessment using exhaled breath condensate leukotriene E4 (EAACI 2026) - "Method Eighteen children with AR (median age: 4 years 7 months) were enrolled and treated with fluticasone furoate for 52 weeks...Conclusion Daily maintenance therapy with intranasal corticosteroids is more effective than as-needed use for long-term management of pediatric AR. Furthermore, LTE4 assessment in EBC is a valuable tool for monitoring airway inflammation in these patients."

Clinical • Allergic Rhinitis • Immunology • Inflammation

MG58-SIT-084: A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis. (clinicaltrialsregister.eu) - P2/3 | N=450 | Not yet recruiting | Sponsor: Inmunotek S.L.

New P2/3 trial • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

FLUTICASONE FUROATE 27.5 MCG AND OXYMETAZOLINE 50MCG AS EFFECTIVE COMBINATION IN ALLERGIC CRS w NP (EAACI 2026) - No abstract available

Immunology

FLUTICASONE FUROATE 27.5 MCG AND OXYMETAZOLINE 50MCG AS EFFECTIVE COMBINATION IN ALLERGIC CRS w NP (EAACI 2026) - No abstract available

Immunology

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study. (PubMed, Clin Exp Allergy) - "Fixed combinations of intranasal antihistamines and corticosteroids were associated with better quality-of-life than oral antihistamines and intranasal antihistamines. These findings could support future cost-effectiveness analyses."

HEOR • Journal • Allergic Rhinitis • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

Differential association of fluticasone furoate and budesonide with clinically detected COVID-19: a retrospective cohort study. (PubMed, BMJ Open Respir Res) - "Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users. The ICS versus non-ICS comparison is exploratory due to confounding by indication and structural imbalance. These findings are hypothesis-generating and warrant prospective studies with systematic testing and stronger designs."

Clinical • Journal • Retrospective data • Asthma • Immunology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma (clinicaltrialsregister.eu) - P2/3 | N=320 | Not yet recruiting | Sponsor: LETI Pharma S.L.U.

New P2/3 trial • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis. (PubMed, Health Technol Assess) - "Twelve months, one puff daily of either dual therapy [55 μg umeclidinium (long-acting muscarinic antagonists) and 22 μg vilanterol (long-acting beta agonists)], triple therapy [dual therapy plus 92 μg fluticasone furoate (inhaled corticosteroid)] or matched placebo dry powder inhalers, randomised in a 2 : 2 : 1 ratio, respectively. These results underscore the importance of completing a large-scale trial of these therapies to help improve the understanding and best treatment for patients with bronchiectasis. This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR127460."

Journal • Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Hyaluronic acid-based microgels loaded with fluticasone furoate for bleomycin-induced acute lung injury treatment. (PubMed, Mater Today Bio) - "In a rat model, intratracheal administration of HPE@FF provided prolonged pulmonary retention for up to 28 days, markedly alleviated pulmonary inflammation, improved histological outcomes, and restored lung function and arterial blood gas levels. Collectively, this study presents an innovative microgel-based drug delivery system that advances the design of steroid formulations and offers promising clinical potential for ALI and related respiratory diseases."

Journal • Acute Lung Injury • Acute Respiratory Distress Syndrome • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL6 • TNFA

Effect of Individualised Homeopathic Medicine as Adjunct to Fluticasone Furoate for Allergic Rhinitis: A Prospective, Randomised, Open-Label, Controlled Trial. (PubMed, Homeopathy) - "No serious adverse events were reported.Adding an IHM to SOC did not enhance clinical outcomes during the 12-week treatment but significantly better symptoms control and quality of life at 18 weeks, suggesting a sustained benefit for AR relapse. These findings support IHMs as potential adjunct for long-term AR management, warranting further investigation."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Diagnosis and management of allergic rhinitis: An Indian expert consensus by otorhinolaryngologists. (PubMed, Asia Pac Allergy) - "Another critical consensus was on the use of the fixed-dose combination of fluticasone furoate and oxymetazoline hydrochloride nasal spray for the persistent and moderate-severe blocker phenotype of AR. This expert consensus will help physicians in their clinical practice and complement effective diagnosis and management of AR."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation • Otorhinolaryngology

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis (clinicaltrials.gov) - P3 | N=68 | Completed | Sponsor: Mahidol University | Recruiting ➔ Completed | Phase classification: PN/A ➔ P3

Phase classification • Trial completion • Allergic Rhinitis • Immunology • Inflammation

A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma. (PubMed, Clin Ther) - "Efficacy and safety of VIL-GLY-FF-MDI were found to be similar to those of IND-GLY-MF-DPI in Indian patients with persistent asthma. Clinical Trial Registry India identifier: CTRI/2024/01/061230."

Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis (WBC 2024) - "Interventions 12 months one puff daily of either dual therapy (55 micrograms umeclidinium [LAMA] and 22 micrograms vilanterol [LABA]), triple therapy (as per dual therapy plus 92 micrograms fluticasone furoate [ICS]) or matched placebo dry powder inhalers, randomised in a 2:2:1 ratio respectively... COVID-19 impacted delivery of the trial effecting staff capacity, set-up timelines and ultimately recruitment to the pilot. The trial is unable to provide evidence on the superiority or cost-effectiveness of LABA/LAMA or ICS/LABA/LAMA to placebo at reducing mean exacerbation rates over 12 months or the non-inferiority of LABA/LAMA to ICS/LABA/LAMA. However, the results do suggest there is a signal of efficacy and that a larger trial may be able to provide evidence."

Clinical • Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Cost-effectiveness analysis of corticosteroid nasal sprays for allergic rhinitis in Japan. (PubMed, Asian Pac J Allergy Immunol) - "Fluticasone propionate is the most cost-effective agent. As it was not often prescribed in the fiscal year 2020, physicians should understand our results to sustain the reduction of healthcare expenditures."

HEOR • Journal • Allergic Rhinitis • Immunology • Inflammation